Last updated: 2026-10-01 03:11:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
CalciMedica, Inc. (CALC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.63, with a market capitalization of $11.47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.58 to $36.00. This page covers its latest market performance, valuation, price trends and company information.
$11.47M | |
$1.67 | |
$2,807.00 | |
$1.58 | |
$1.61 | |
36.52K | |
77.77K | |
-- | |
$36.00 | |
$1.58 | |
-- | |
-- |
CalciMedica, Inc. (CALC) last closed at $1.61 as of 2026-09-30 23:59:00, unchanged from the previous close of $1.61.
During the latest regular trading session, CALC traded between $1.58 and $2,807.00, with a volume of 36.52K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, CalciMedica, Inc. (CALC) moved from $1.86 to $1.63, representing a decline of 12.63% ($0.24).
The stock traded between $1.58 and $1.98 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 54.75 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0.1%
CALC is currently trading at $1.63, placing it 0.1% of the way from its 52-week low of $1.58 to its 52-week high of $36.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CalciMedica, Inc. (CALC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.